Lilly Claims Zydus Broke Deal In Strattera Row

Law360, New York (May 9, 2011, 2:13 PM EDT) -- Eli Lilly & Co. slapped Zydus Pharmaceuticals USA Inc. with a patent infringement suit Thursday in New Jersey, accusing it of breaching a consent order entered in a previous case Lilly brought over attention deficit hyperactivity disorder treatment Strattera.

Lilly's complaint, filed in federal court in Newark, said Zydus' bid for approval for 10-milligram generic Strattera capsules came with a Paragraph IV certification claiming that a patent for the drug is invalid, even though Zydus stipulated that the patent was not invalid in the December 2007...
To view the full article, register now.